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Flow cytometryAbstract Emerging data have implicated a critical role for CD4 in the pathogenesis of systemic
lupus erythematosus (SLE). This study was designed to delineate the contribution of CD4+ T cells
in the pathogenesis of SLE disease. Forty-four patients (3 male: 41 female) and 20 healthy volun-
teers (4 male: 16 female) were included in the study. CD4+ lymphocytes analysis was done using
three-color ﬂow cytometry with antibodies against human-CD95, a prototype cell death receptor,
and the chemokine receptor-7 (CCR7) after gating for lymphocytes based on the forward and side
scatter. Serum levels of IL-6, IL-12, IL-17, TNF-a and IL-10 cytokines were assayed using ELISA.
Disease activity was assessed using the SLE disease activity index (SLEDAI). Based on the expres-
sion of CCR7 and CD95, CD4+ lymphocytes were subdivided into three particular subsets;
CD4+CD95+CCR7+ cells, CD4+CD95CCR7+ cells and CD4+CD95+CCR7 cells.
Percentage of CD4+CD95+CCR7+ cell subset was signiﬁcantly higher in patients with SLE with
102 A.M. Aldahlawi et al.active disease (SLEDAI > 6) and inactive (SLEDAI < 6) as compared with controls (P= 0.005),
and it showed a signiﬁcant positive correlation with ANA titer (P = 0.01), and a negative correla-
tion with WBCs count (P= 0.001). CD4+CD95+CCR7 cell subset was signiﬁcantly higher in
active SLE patients in comparison to patients with inactive disease and controls (P= 0.05,
P= 0.005 respectively), and it correlates positively with SLEDAI, IL-6 and IL-17 levels
(P= 0.001, 0.05, 0.01 respectively), and negatively with blood WBCs counts (P= 0.001). The third
CD4+CD95CCR7+cell subset was found signiﬁcantly lower in SLE patients compared with con-
trols, and it was found negatively correlated with IL-10, IL-6, and IL-17. The results show that
CD4+CD95+subset lacking expression of CCR7 is associated with cell mediated inﬂammatory
response as manifested by its correlation with signs of inﬂammation, inﬂammatory cytokines and
disease activity index. Whereas, CD4+CD95+CCR7+ correlate more with antibody immune
responses as manifested by association with serum ANA. These data suggest disparate roles of these
cell subsets in the pathophysiology of SLE. A better understanding of the characteristics of CD4 cell
subsets may shed light on the pathogenesis of autoimmune diseases, particularly SLE.
ª 2015 TheAuthors. Production and hosting by Elsevier B.V. on behalf ofKing SaudUniversity. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Systemic lupus erythematosus (SLE) is one of the most com-
mon autoimmune diseases that can affect multiple organs
and body systems. The etiology of the disease remains unclear;
however, it is thought to be triggered by autoantigens that
induce autoantibody production. Apoptotic lymphocytes
may be one source of autoantigens, and increased numbers
of apoptotic lymphocytes have been reported in SLE (Shah
et al., 2011). Notably, apoptotic CD4+, but not CD8+, T lym-
phocytes were found to constitute the main source for the acti-
vated lymphocyte derived DNA and other apoptotic cellular
constituents that function as autoantigens to induce produc-
tion of anti-double-stranded DNA (anti-dsDNA) antibodies
in SLE (Wen et al., 2012).
Several studies reported increased levels of apoptotic
CD4+lymphocytes in SLE patients; these lymphocytes are
characterized by the expression of CD95, (Fas/APO-1), the
prototypic death receptor of the immune system (Bijl et al.,
2001; Xue et al., 2006). CD95 is a member of the TNF receptor
superfamily, whose ligand, CD95L (FasL), is expressed on acti-
vated; but not resting T cells (Garrone et al., 1995; Genestier
et al., 1998). In addition to its role in apoptosis, CD95 binding
to its agonist was found to activate the nuclear factor-kappa B
(NF-jB), a transcriptional factor that plays critical roles in
inﬂammation, immunity, cell proliferation, differentiation,
and survival (Rensing-Ehl et al., 1995). NF-jB is involved in
the transcriptional regulation of many cytokine (Rensing-Ehl
et al., 1995), and chemokine (Liu et al., 2004; Tang et al.,
2009) genes expressed in activated lymphocytes. Thus, in addi-
tion to provoking apoptosis, CD95 receptor stimulation can
indirectly trigger inﬂammation and lymphocyte migration to
lymph nodes or inﬂamed peripheral tissues (Cullen et al., 2013).
In essence, the interaction between T-B lymphocytes occur-
ring in lymphoid tissues requires the migration of T and B-cells
to their speciﬁed T- and B-cell zones in lymphoid tissue where
they encounter dendritic cells and antigens (Eriksson and
Rantapaa-Dahlqvist, 2014). This process depends on migration
of CD4+ T cell to secondary lymphoid organs and the multi-
tude of autoantigens that can provide. Previous investigations
show that CD4+ T cells expressing the chemokine receptor-7
(CCR7), which recognizes CCL19 and CCL21, are attractedclose to B cell follicles where it triggers the activation and dif-
ferentiation (T-cell help) of B cells in germinal centers of the
lymphoid tissue (MacLennan, 1994; Okada and Cyster, 2006).
The aforementioned data suggest that the surface receptor
CD95 is involved in other physiological functions besides apop-
totic signaling, such as inﬂammation cytokine and/or chemo-
kine receptor expression. Therefore, we aimed to investigate
the extent of CD4+ lymphocytes expressing CD95 and their
association with chemokine receptor CCR7 expression, inﬂam-
matory cytokines and disease activity in patients with SLE.
2. Materials and methods
2.1. Patients
A total of 44 SLE patients were classiﬁed according to the SLE
disease activity index (SLEDAI) (Bombardier et al., 1992), into
active group deﬁned as SLEDAI score >6 (included 3 males
and 23 Females) patients, and inactive group deﬁned as
SLEDAI score less than 6 (included 18 females). Twenty
healthy volunteers (4 males and 16 females), who were clinically
and laboratory free of any autoimmune diseases, served as a
control group. All patients have provided written informed
consent for study inclusion and the anonymous use of their
data from lupus disease registry. The King Abdulaziz
University Hospital Ethics Committee has approved the study.
2.2. Clinical and laboratory assessments
Clinical and demographic characteristics were recorded for all
patients shown in (Table 1). Levels of anti-nuclear antibodies
(ANA), anti-dsDNA antibody, C-reactive protein (CRP), ery-
throcyte sedimentation rate (ESR), complete blood count
(CBC), complement (C)-3, C4, urine analysis were assayed
using commercially available kits according to the manufac-
turer’s instructions.
2.3. Flow cytometry analysis
Peripheral blood mononuclear cells (PBMCs) were analyzed by
three-color ﬂow cytometry using CD95-FITC, CCR7-PE, and
Table 1 Demographic, clinical and laboratory data for the studied groups.
Parameters Active SLE (n= 26) Inactive SLE (n= 18) HCs (n= 20)
Demographic and clinical data
Gender (male/female) 3/23 0/18 4/16
Age (years) 35.44 ± 11.36 31.81 ± 10.21 29.15 ± 4.74
Disease duration (years) 5.88 ± 3.99 4.86 ± 1.43
SLEDAI 15.57 ± 7.69 3.5 ± 2
Laboratory data
IL-6 (ng/ml) 9.55 ± 2.23a 9.72 ± 1.91a 3.47 ± 1.41
IL-12 (ng/ml) 21.59 ± 1.66a 22.71 ± 0.67a 15.42 ± 1.16
TNF-a (ng/ml) 19.49 ± 2.18a,b 16.83 ± 1.54a 8.99 ± 0.47
IL-17 (ng/ml) 41.65 ± 2.13a,b 33.53 ± 2.11a 27.47 ± 1.29
IL-10 (ng/ml) 21.9 ± 2.43a 19.27 ± 2.35a 13.83 ± 1.35
ANA (IU/ml) 0.75 ± 0.33a 0.53 ± 0.39 a 0.11 ± 0.04
Anti ds-DNA (IU/ml) 665.85 ± 401.2b 445.52 ± 217.44 Neg.
C3 (g/L) (0.75–1.65) 0.84 ± 0.32a 0.93 ± 0.34 0.78 ± 0.14
C4 (g/L) (0.2–0.6) 0.14 ± 0.43a 0.16 ± 0.09 0.29 ± 0.07
CRP (mg/L) 4.85 ± 2.16a 4.99 ± 3.57a 2.46 ± 0.19
ESR (mm/H) 25.64 ± 16.25a 26.81 ± 13.21a 11.8 ± 6.25
WBC (K/UL) 3.35 ± 1.58a,b 5.57 ± 1.26 8.64 ± 2.99
RBC (M/UL) 4.50 ± 0.69 4.27 ± 0.72 4.52 ± 0.47
PLT (K/UL) 279.07 ± 68.16 243.13 ± 67.05 268.4 ± 71.02
WBC in urine 9.43 ± 6.13b 2.24 ± 2.41 –
RBC in urine 8.71 ± 7.87b 2.24 ± 2.12 –
Values represent mean ± S.D. of means. Superscript letter ‘‘a’’ refers to signiﬁcant difference in comparison with control group, and ‘‘b’’ with
inactive SLE group. The difference is signiﬁcant at P< 0.05 levels.
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mine the nonspeciﬁc binding. All monoclonal antibodies were
purchased from R&D system (Minneapolis MN, USA). Flow
cytometry analysis was performed on BD FACSCalibur ﬂow
cytometer and 10,000 events were acquired using Cell Quest
Software (BD Biosciences, San Jose, CA, USA). Data were
analyzed with the Summit v4.3 Build 2445 software (Dako
Colorado Inc., Fort Collins, CO, USA). Percentages of apop-
totic CD4 lymphocytes were determined after gating on the for-
ward scatter and side scatter properties of lymphocytes and the
CD4-Percp positive population (Fig. 1).
2.4. Cytokine measurement
Serum concentrations of pro-inﬂammatory (IL-6, IL-12, IL-17
and TNF-a) and anti-inﬂammatory (IL-10) cytokines were
assayed by using commercial ELISA kits (ELISA MAX
Deluxe Sets, BioLegened; San Diego CA, USA). All measure-
ments were performed in duplicate according to the manufac-
ture’s recommendations.
2.5. Statistical analysis
All data were statistically analyzed using Statistical Package for
Social Sciences (SPSS) V20.0. The data were expressed as
means ± standard deviation (SD). Correlations were done using
Pearson tests, and analyses of variance were done using ANOVA
test followed byBonferroni correction.P-value less than or equal
to 0.05 is considered as being statistically signiﬁcant.
3. Results
Table 1 presents the demographic, clinical and laboratory data
for the studied groups. It is apparent that there is a signiﬁcantdifference (P= 0.0001) in SLEDAI between active and inac-
tive groups, whereas, the differences in age and number of
abortions and pregnancies (in female patients) and disease
duration did not show statistical signiﬁcance.
The concentrations of TNF-a and IL-17 were signiﬁcantly
higher in the active SLE group than that of inactive SLE
(P= 0.05, P= 0.02 respectively) and healthy (P= 0.01,
P= 0.001 respectively) subjects. Whereas the concentrations
of IL-6, IL-10 and IL-12 cytokines were signiﬁcantly higher
in both active and inactive SLE patients compared with
healthy controls (Table 1).
Expression of CD95 and CCR7 was analyzed on CD4+ T
cells that yield three subsets of CD4 T-cells (Fig. 1). The ﬁrst
subset consists of CD4+CD95+CCR7+cells that were found
signiﬁcantly higher in active and inactive SLE patients than
the healthy control group (43 ± 2.7% and 42 ± 2.2 vs.
13 ± 1.4, P< 0.0001). The second cell population includes
CD4+CD95+CCR7 cells which were signiﬁcantly higher in
active (29 ± 7.2%) than inactive (21.9 ± 5.6%) and healthy
subjects (18 ± 4.8%) (P= 0.05 and 0.01 respectively). The
third CD4+CD95CCR7+ T cell population was signiﬁcantly
higher in control subjects than that in the active SLE group
and the inactive SLE group (49 ± 5.1% vs. 28 ± 13.2% and
31 ± 11.45), (both at P< 0.05) (Fig. 1).
The correlations of each CD4+ T cell subset with other
clinical and biochemical parameters are presented in Table 2.
CD4+CD95+CCR7+ cells showed a positive correlation with
IL-10 and ANA (r= 0.499, P= 0.01; r= 0.757, P= 0.001
respectively), and a negative correlation with blood WBCs
count (r= 0.462, P= 0.05). CD4+CD95+CCR7 cells cor-
related positively with number of abortions, SLEDAI, IL-6
and IL-17 concentrations (r= 0.465, P= 0.02; r= 0.608,
P= 0.001; r= 0.595, P= 0.01 and r= 0.770, P= 0.001
respectively). Whereas, CD4+CD95CCR7+ cells correlated
Figure 1 (A–C) Example of the gating strategy used to identify CD4+ T cell-subsets according to expressing of CD95 and CCR7. Gates
were set around lymphocytes, as deﬁned by forward and side light scatter (A), and then gating on CD4+ bright positive cells (B). The two
gates were applied to the lower dot plot (C) displaying CCR7 and CD95.
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(r= 0.595, P= 0.01; r= 0.587, P= 0.02; r= 0.410,
P= 0.05, respectively, (Table 2).4. Discussion
The clinical course of SLE disease is heterogeneous with alter-
nating ﬂares periods of increased disease activity and remissions,
when pain and inﬂammation disappear. The reasons behind this
ﬂuctuation in disease activity are unclear; however evidence sug-
gests that apoptotic lymphocytes likely account for this phe-
nomenon. As apoptotic lymphocytes, particularly CD4+
lymphocytes, were found to serve as a source for autoantigens
and increase the production of ANA and anti-dsDNA antibod-
ies that are considered hallmarks of SLE (Wen et al., 2012).In the present study, we found that SLE patients had an
increased percentage of CD4+ lymphocytes expressing
CD95, the prototype marker of apoptosis, indicating an
increased apoptosis of these cells in SLE patients in vivo.
This ﬁnding conﬁrms earlier observations of Wen et al.
(2012) that CD95 is upregulated upon activation in SLE.
Other studies reported that T cells with increased CD95 anti-
gen expression might be highly susceptible to apoptotic cell
death in vivo (Amasaki et al., 1995; Silvestris et al., 2002).
Cell death of CD4 lymphocytes by apoptosis represents a
putative mechanism for providing an excessive load of
apoptotic particles containing nuclear antigens or of immune
complexes containing autoantigens that can overcome self-
tolerance mechanisms and trigger autoimmunity (Gabler
et al., 2003). However, this seems to depend on two processes,
CD4+ T cell activation and migration to secondary lymphoid
Table 2 Correlations between CD4+ T cell subsets and clinical parameters in studied groups.
Parameter CD4+ cell subsets
CD4+CD95+CCR7+ CD4+CD95+CCR7 CD4+CD95CCR7+
Demographic & clinical data
Age 0.192 0.089 0.302
No. pregnancy 0.063 0.224 0.402
No. Of abortion 0.306 0.456* 0.013
Disease duration 0.001 0.040 0.221
SLEDAI 0.244 0.608** 0.256
Laboratory data
IL-6 0.233 0.595* 0.164
IL-10 0.499* 0.127 0.595*
IL-12 0.383 0.164 0.131
IL-17 0.304 0.770** 0.587*
TNF-alpha 0.341 0.341 0.410*
ANA 0.757** 0.302 0.123
dsDNA 0.246 0.260 0.047
C3 0.008 0.203 0.097
C4 0.172 0.119 0.125
CR-P 0.027 0.097 0.011
ESR 0.023 0.346 0.253
WBCs 0.490* 0.124 0.270
RBs 0.359 0.201 0.403
PLT 0.183 0.099 0.190
WBC (urine) 0.327 0.182 0.230
RBC (urine) 0.054 0.012 0.092
Total protein 0.329 0 .258 0.123
** Correlation is signiﬁcant at the 0.01 level (2-tailed).
* Correlation is signiﬁcant at the 0.05 level (2-tailed).
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Previous investigations showed that T-helper lymphocytes
expressing the chemokine receptor CCR7, which recognizes
CCL19 and CCL21 chemokines, are attracted close to B cell
follicles where it triggers the activation and differentiation of
B cells in germinal centers of lymphoid tissue (Okada and
Cyster, 2006; Sallusto et al., 2000).
In our study, the expression of CCR7 and CD95 on CD4+
lymphocytes identiﬁed three particular subsets that are
CD4+CD95+CCR7+ cells, CD4+CD95CCR7+ cells and
CD4+CD95+CCR7 cells. CD4+CD95+CCR7+ cells-
subset was found signiﬁcantly increased in the blood of both
active and inactive SLE patients in comparison to healthy indi-
viduals. This cell subset showed a signiﬁcant positive correla-
tion only with serum IL-10 cells and ANA titer (P= 0.04
and 0.004 respectively). IL-10 is a cytokine mainly produced
by B cells, which use it to support their activation and anti-
body production (Tyrrell-Price et al., 2001; Xu et al., 2004).
This may explain our ﬁnding of the concomitant positive cor-
relation between IL-10 and ANA titer and their association
with SLEDAI.
In their study of the different types of CD4+cell subsets;
Sallusto et al. (1999) found that a subset of CD4+ cells that
express CCR7+ home to the T cell areas of lymphoid organs
where they readily proliferate and differentiate into effector
cells, marked by the downregulation of CCR7. Recently, this
subset of effector CD4+CCR7 T cells was found migrate to
inﬂamed tissues and display immediate effector functions
(Sallusto et al., 2014). In addition, it was found that lack of
CCR7 associated with the manifestation of spontaneous
autoimmunity (Forster et al., 2008). Furthermore, Kuwabaraet al. (2009) demonstrated that a large proportion of CCR7
cells is Th17 population that home to inﬂamed tissues and
secretes inﬂammatory cytokines mainly IL-17, IL-6 and
TNF-a in autoimmune encephalomyelitis. In line with these
data, our results showed that CD4+CD95+CCR7 T cells
correlated positively with signs of inﬂammation including
number of recurrent spontaneous abortions in female patients
and SLEDAI (P< 0.033 and 0.005 respectively). In addition,
this cell subset showed signiﬁcant positive correlations with
pro-inﬂammatory cytokines IL-6 and IL-17 (P< 0.012 and
0.003 respectively).
IL-17 is an essential cytokine in the pathogenesis of SLE,
particularly in the development of tissue damage
(Apostolidis et al., 2011). Increased production IL-17 in
patients with SLE was found to amplify the immune response
by augmenting the production of antibodies by B cells (Crispin
and Tsokos, 2010). Th17 cells were found increasing target-
organ inﬂammation by producing several kinds of inﬂamma-
tory cytokines in addition to IL-17, including TNF-a and
IL-6 that may exacerbate SLE disease activity (Rana et al.,
2012). The positive correlation between CD4+CD95+
CCR7 cells and IL-17 in the present study may explain their
association with various clinical manifestations of inﬂamma-
tion, and disease activity as manifested by SLEDAI.
The third subset of cells we found is CD4+CD95CCR7+
lymphocytes, which showed a signiﬁcant higher percentage in
healthy subjects, compared with SLE groups. This subset of
cells showed a signiﬁcant negative correlation with IL-10
(P< 0.026), IL-17 (P< 0.012), and TNF-a (P< 0.029), that
may suggest their involvement in anti-inﬂammatory response.
These data are in line with previous studies which reported
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T-cells are associated with a more anti-inﬂammatory proﬁle
(Gordon et al., 1996; Ugarte-Gil et al., 2014). The persistence
of autoreactive memory cells is thought to be involved in the
repeated cycles of remission and recurrent inﬂammation in
SLE (Alecsandru et al., 2011; Leiva et al., 2013).
In conclusion, the present results suggest profound differ-
ences between the two CD4+ cell subsets according to the
expression of CD95 and CCR7. One subset
CD4+CD95+CCR7+ might have a role inactivation of
humoral immune response and increasing ANA titer in one
hand, whereas CD4+CD95+CCR7 cells subset seem to be
involved in inﬂammatory response and disease activity as indi-
cated by association with inﬂammatory cytokines IL-17 and
IL-6. Taken together, our results suggest that both
CD4+CD95+ cell subsets expressing and lacking the expres-
sion of CCR7 have variable roles in the pathophysiology of
SLE. A better understanding of the characteristics of these
cells may shed light on the pathogenesis of autoimmune dis-
eases, particularly SLE.References
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